HIV Citations List: January 2023

Literature Citations

1. HIV-Tat Exacerbates the Actions of Atazanavir, Efavirenz, and Ritonavir on Cardiac Ryanodine Receptor (RyR2). Alomar, F.A., C. Tian, S.R. Bidasee, Z.L. Venn, E. Schroder, N.Y. Palermo, M. AlShabeeb, B.J. Edagwa, J.J. Payne, and K.R. Bidasee. International Journal of Molecular Sciences, 2022. 24(1): 274. PMID[36613717]. PMCID[PMC9820108].
[PubMed]. HIV_01_2023.

2. Synthesis of Selenoesters via Aldol Condensation and/or Conjugate Reduction and Their Antiviral Activities. Boateng, A., M. Amano, and M. Sugiura. ACS Omega, 2023. 8(1): 1369-1374. PMID[36643423]. PMCID[PMC9835172].
[PubMed]. HIV_01_2023.

3. Bioactive Icetexane and Abietane Diterpenes from Isodon phyllopodus. Deng, R., J. Zou, C.L. Zhao, Y.M. Yang, C.F. Ku, Y. Zhu, Z.M. Liang, J.H. Ye, L.T. Pan, and H.J. Zhang. Natural Product Research, 2023. 37(1): 68-76. PMID[34498960].
[PubMed]. HIV_01_2023.

4. Pharmacological Inhibition of IKK to Tackle Latency and Hyperinflammation in Chronic HIV-1 Infection. Ezeonwumelu, I.J., E. Garcia-Vidal, E. Riveira-Muñoz, E. Felip, L. Gutiérrez-Chamorro, I. Calba, M. Massanella, G. Sirera, B. Clotet, E. Ballana, and R. Badia. International Journal of Molecular Sciences, 2022. 23(23): 15000. PMID[36499329]. PMCID[PMC9741028].
[PubMed]. HIV_01_2023.

5. Disubstituted Pyrimidine-5-carboxamide Derivatives as Novel HIV-1 NNRTIs: Crystallographic Overlay-based Molecular Design, Synthesis, and Biological Evaluation. Feng, D., H. Lin, L. Jiang, J. Dai, X. Zhang, Z. Zhou, Y. Sun, Z. Wang, E. Clercq, C. Pannecouque, D. Kang, P. Zhan, and X. Liu. European Journal of Medicinal Chemistry, 2023. 246: 114957. PMID[36446205].
[PubMed]. HIV_01_2023.

6. Derivatives of 3'-Azidothymidine with 6-Cyanopyridone as Base or as Phosphoramidate Ester and Their Antiretroviral Activity. Han, J.Y., J. Arnold, C. Pannecouque, G. Andrei, R. Snoeck, and C. Richert. Helvetica Chimica Acta, 2022. 106(1): e202200157. ISI[000905229000001].
[WOS]. HIV_01_2023.

7. 4-Phenylquinoline-8-amine Induces HIV-1 Reactivation and Apoptosis in Latently HIV-1 Infected Cells. Kitamura, H., S. Sukegawa, K. Matsuda, K. Tanimoto, T. Kobayakawa, K. Takahashi, H. Tamamura, K. Tsuchiya, H. Gatanaga, K. Maeda, and H. Takeuchi. Biochemical and Biophysical Research Communications, 2023. 641: 139-147. PMID[36527748].
[PubMed]. HIV_01_2023.

8. Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates. Matsumoto, K., T. Kuwata, W.D. Tolbert, J. Richard, S. Ding, J. Prévost, S. Takahama, G.P. Judicate, T. Ueno, H. Nakata, T. Kobayakawa, K. Tsuji, H. Tamamura, A.B. Smith, 3rd, M. Pazgier, A. Finzi, and S. Matsushita. Journal of Virology, 2023. 97(1): e0163822. PMID[36511698]. PMCID[PMC9888228].
[PubMed]. HIV_01_2023.

9. Hybrids of Delavirdine and Piperdin-4-yl-aminopyrimidines (DPAPYs) as Potent HIV-1 NNRTIs: Design, Synthesis and Biological Activities. Ming, W., W.L. Lu, C. Pannecouque, J. Chen, H.F. Wang, Y.Q. Xiao, S. Hu, S.X. Gu, Y.Y. Zhu, and F.E. Chen. European Journal of Medicinal Chemistry, 2023. 248: 115114. PMID[36640458].
[PubMed]. HIV_01_2023.

10. Intrinsic Resistance of HIV-2 and SIV to the Maturation Inhibitor GSK2838232. Smith, R.A., D.N. Raugi, R.S. Nixon, J. Song, M. Seydi, and G.S. Gottlieb. Plos One, 2023. 18(1): e0280568. PMID[36652466]. PMCID[PMC9847912].
[PubMed]. HIV_01_2023.

11. Structure-based Identification of Natural-product-derived Compounds with Potential to Inhibit HIV-1 Entry. Ugwu-Korie, N., O. Quaye, E. Wright, S. Languon, O. Agyapong, E. Broni, Y. Gupta, P. Kempaiah, and S.K. Kwofie. Molecules, 2023. 28(2): 474. PMID[36677538]. PMCID[PMC9865492].
[PubMed]. HIV_01_2023.

12. Anti-HIV Potential of Beesioside I Derivatives as Maturation Inhibitors: Synthesis, 3D-QSAR, Molecular Docking and Molecular Dynamics Simulations. Zhao, Z., Y. Ma, X. Li, S.L. Morris-Natschke, Z. Sun, Z. Sun, G. Ma, Z. Dong, X. Zhao, M. Yang, X. Xu, K. Lee, H. Wu, and C. Chen. International Journal of Molecular Sciences, 2023. 24(2): 1430. PMID[36674943]. PMCID[PMC9867151].
[PubMed]. HIV_01_2023.

13. Structure-guided Design of Novel HEPT Analogs with Enhanced Potency and Safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs. Zhou, R.L., Z. Ju, C. Pannecouque, E. Clercq, S. Wang, and F.E. Chen. European Journal of Medicinal Chemistry, 2023. 246: 114939. PMID[36442370].
[PubMed]. HIV_01_2023.

14. Covalently Targeted Highly Conserved Tyr318 to Improve the Drug Resistance Profiles of HIV-1 NNRTIs: A Proof-of-concept Study. Zhou, Z., B. Meng, J. An, F. Zhao, Y. Sun, D. Zeng, W. Wang, S. Gao, Y. Xia, C. Dun, E. De Clercq, C. Pannecouque, P. Zhan, D. Kang, and X. Liu. International Journal of Molecular Sciences, 2023. 24(2): 1215. PMID[36674730]. PMCID[PMC9865928].
[PubMed]. HIV_01_2023.

Patent Citations

15. Engineered Bacteriophage T4 Nanoparticles as a Potential Targeted Activator of HIV-1 Latency in CD4+ Human T-Cells. Rao, V.B. and H. Batra. Patent. 2023. WO2022-IB56234 2023285922: 81 pages.
[Patent]. HIV_01_2023.